Cargando…

Prolonged progression‐free survival achieved by octreotide LAR plus transarterial embolization in low‐to‐intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden

OBJECTIVE: To evaluate the efficacy and outcome of transarterial embolization (TAE) plus octreotide long‐acting repeatable (LAR) on patients with low‐to‐intermediate neuroendocrine tumor liver metastases (NETLM). METHODS: One hundred and sixteen patients with G1/G2 NETLM treated with TAE plus octreo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yiming, Liu, Haikuan, Chen, Wenchuan, Yu, Hang, Yao, Wang, Fan, Wenzhe, Li, Jiaping, Chen, Minhu, Chen, Jie, Wang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249979/ https://www.ncbi.nlm.nih.gov/pubmed/35289113 http://dx.doi.org/10.1002/cam4.4628

Ejemplares similares

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour
por: Abell, Sally K, et al.
Publicado: (2015)

Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2016)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023)

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015)

E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
por: Lubner, Sam, et al.
Publicado: (2018)

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
por: Exner, Samantha, et al.
Publicado: (2018)

Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011)

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
por: Kvols, L. K., et al.
Publicado: (1992)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau, Hanford, et al.
Publicado: (2017)

Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study
por: Kirzinger, Lukas, et al.
Publicado: (2016)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR
por: Yanagisawa, Asako, et al.
Publicado: (2017)

Refractory Thrombocytopenia Responds to Octreotide Treatment in a Case of Evans Syndrome with Gastric Neuroendocrine Tumor
por: Chung-Delgado, Kocfa, et al.
Publicado: (2013)

Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
por: Chen, Shuling, et al.
Publicado: (2019)

Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis
por: Kapralos, Iasonas, et al.
Publicado: (2021)

Octreotide Conjugates for Tumor Targeting and Imaging
por: Figueras, Eduard, et al.
Publicado: (2019)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
por: Al-Efraij, Khalid, et al.
Publicado: (2015)

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
por: Berruti, Alfredo, et al.
Publicado: (2014)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015)

Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma)
por: Hiraide, Sakura, et al.
Publicado: (2017)

Diagnostic accuracy of technetium-99m-octreotide in imaging neuroendocrine tumors, Oman hospital experience with literature review
por: Al Bulushi, Naima, et al.
Publicado: (2019)

Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
por: Chin, Sang Ouk, et al.
Publicado: (2015)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR
por: Porto, Lara Benigno, et al.
Publicado: (2018)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

(68)Ga-DOTATATE PET/CT versus (111)In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
por: Cavicchioli, Marcelo, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Fan, Wenzhe, et al.
Publicado: (2015)

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
por: Caraglia, M, et al.
Publicado: (2011)

Uneventful octreotide LAR therapy throughout three pregnancies, with favorable delivery and anthropometric measures for each newborn: a case report
por: Naccache, Deeb Daoud, et al.
Publicado: (2011)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature
por: Kemm, Matthew H., et al.
Publicado: (2019)

Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review
por: Shirley, Lawrence A, et al.
Publicado: (2015)

SAT-435 Optimization of Pharmacological Treatment of Acromegaly: Impact on IGF-1 Levels Comparing Isolated Octreotide LAR and Combined Pharmacological Therapy
por: Naves, Luciana, et al.
Publicado: (2019)

Giant mediastinal neuroendocrine tumor successfully resected after transarterial chemoembolization of drug-eluting embolic microspheres: A case report
por: Yu, Qi, et al.
Publicado: (2021)

Hepatic Hilar Block as an Adjunct to Transarterial Embolization of Neuroendocrine Tumors: A Retrospective Review of Safety and Efficacy
por: Jain, Samagra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b9m3hrmbsulv1u6kmu9p2ruegm